We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

59 hedge funds and large institutions have $110M invested in Spero Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

3% less funds holding

Funds holding: 61 → 59 (-2)

5.14% less ownership

Funds ownership: 60.74% → 55.6% (-5.1%)

10% less capital invested

Capital invested by funds: $122M → $110M (-$12.4M)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
1.29%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
6
Increased
27
Reduced
12
Closed
8
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$627K
2
PAM
Panagora Asset Management
Massachusetts
+$533K
3
Renaissance Technologies
Renaissance Technologies
New York
+$399K
4
State Street
State Street
Massachusetts
+$292K
5
Northern Trust
Northern Trust
Illinois
+$278K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$3.86M
2
FI
Fosun International
China
-$962K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$615K
4
DCM
DAFNA Capital Management
California
-$323K
5
Marshall Wace
Marshall Wace
United Kingdom
-$204K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
51
Prelude Capital Management
New York
$7K +$2.11K +200 +40%
RE
52
RBC Europe
United Kingdom
$6.34K – – –
MAM
53
Meeder Asset Management
Ohio
$6K -$10.1K -959 -64%
AIP
54
Ameritas Investment Partners
Nebraska
$5K – – –
US Bancorp
55
US Bancorp
Minnesota
$5K +$5.27K +500 New
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$3K +$1.05K +100 +50%
TRCT
57
Tower Research Capital (TRC)
New York
$2K -$5.22K -495 -69%
TFA
58
Toth Financial Advisory
Virginia
$2K +$1.58K +150 New
Group One Trading
59
Group One Trading
Illinois
$1K – – –
FI
60
Fosun International
China
– -$962K -86,596 Closed
Marshall Wace
61
Marshall Wace
United Kingdom
– -$204K -17,699 Closed
KBC Group
62
KBC Group
Belgium
– -$80K -6,935 Closed
Acadian Asset Management
63
Acadian Asset Management
Massachusetts
– -$25K -2,204 Closed
PCP
64
Proficio Capital Partners
Massachusetts
– -$7K -590 Closed
Twin Tree Management
65
Twin Tree Management
Texas
– -$6K -550 Closed
EWM
66
Executive Wealth Management
Michigan
– -$5K -413 Closed
1 2
3

SPRO Hedge Fund Activity: Q3 2019 in Review

59 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2019, worth a combined $110M — down 10% from $122M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SPRO and 6 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 27 added.

The largest buyer was Vanguard Group, adding an estimated $627K. The largest seller was OrbiMed, cutting an estimated $3.86M.

  • 59 institutional investors held Spero Therapeutics (SPRO) as of Q3 2019, down from 61 in Q2 2019.
  • Funds reported $110M of Spero Therapeutics stock for Q3 2019, down 10% quarter-over-quarter.
  • 6 funds opened new Spero Therapeutics positions in Q3 2019 and 8 closed out, a net change of -2 holders.
  • The largest Spero Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $627K added.
  • The largest Spero Therapeutics seller in Q3 2019 was OrbiMed, an estimated $3.86M sold.

Based on aggregated 13F filings for Q3 2019.